Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxifluridine + levoleucovorin
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Doxifluridine + levoleucovorin is an all-oral chemotherapy regimen combining doxifluridine (a prodrug of 5-fluorouracil) with levoleucovorin (a biomodulator). This combination has been studied for the treatment of advanced colorectal cancer and breast cancer, particularly in elderly patients. The regimen shows good efficacy with manageable side effects and excellent patient compliance.
- Other names
- 5-dFUR + l-leucovorin
02
Targets
TS (Thymidylate synthase)
Beyond the preview
Go deeper on doxifluridine + levoleucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxifluridine + levoleucovorin.